People with type 2 diabetes who combined healthy lifestyle habits with GLP-1 receptor agonist (GLP-1 RA) medications had a greater reduction in risk of major adverse cardiovascular events, including heart attack, stroke or cardiovascular disease death, compared to people only taking the medication, according to a preliminary study presented at the American Heart Association's Scientific Sessions 2025, held Nov. 7–10, in New Orleans.
Subscribe to our newsletter for the latest sci-tech news updates.
"Lifestyle modifications are recommended as the cornerstone for preventing and managing type 2 diabetes," said lead study author, Xuan-Mai Nguyen, M.D., Ph.D., a researcher with the Department of Veterans Affairs Boston Health Care System and second-year medicine resident at the University of California, Los Angeles.
"Our study's findings suggest that people with type 2 diabetes taking GLP-1 receptor agonists can improve their heart health even more by adding and maintaining healthy lifestyle habits. They also indicate that if someone does not have access to GLP-1 RAs, adopting healthy lifestyle habits can still lower the risk of having a stroke, heart attack or dying from heart-related issues."
People living with type 2 diabetes are twice as likely to die from cardiovascular disease, according to"Know Diabetes by Heart"—a collaborative initiative of the American Heart Association and the American Diabetes Association. The incidence of type 2 diabetes has more than doubled in the past 20 years in the U.S.
GLP-1 RA medications are injectable medications that lower blood sugar to treat diabetes, but also reduce appetite and can be used for weight loss. While research has proven the positive impact of the medications on heart health, and it is well known that healthy lifestyle factors can lead to a healthier heart, this study investigated how lifestyle factors influenced the association between GLP-1 RA medications and heart outcomes in people with type 2 diabetes.
Researchers reviewed health information of people within the Million Veteran Program, a national program that studies how genes, lifestyle, military experiences and exposures affect health and wellness in U.S. veterans. The program uses data from medical records, biospecimens and self-reported surveys.
The study included data for more than 63,000 veterans who had type 2 diabetes with no previous history of heart attack, stroke, cancer or advanced chronic kidney disease. Information was gathered on heart-healthy lifestyle habits, including healthy eating, physical activity, not smoking, restful sleep, no-to-moderate alcohol intake, good stress management, social connection and support and no opioid addiction.
Researchers analyzed different combinations of lifestyle factors and medication use, with comparisons of people using GLP-1 RAs versus people not using this class of medication and also considered the number of protective lifestyle habits reported by each study participant.
Researchers then calculated each participant's risk of major adverse cardiovascular events, which included non-fatal heart attacks, non-fatal strokes, and death due to cardiac issues. When examined individually, all of the healthy lifestyle factors were independently associated with the participants having a lower likelihood of major adverse cardiovascular events.
The analysis also found:
"Taking a GLP-1 RA alone is less effective than combining it with other beneficial lifestyle factors. Achieving some healthy lifestyle behaviors can lower the risk of a major adverse cardiovascular event," Nguyen said. "The more healthy lifestyle factors adopted, the better."
Chiadi E. Ndumele, M.D., Ph.D., FAHA, chair of the American Heart Association's Council on Lifestyle and Cardiometabolic Health, noted that "This is a very interesting study with powerful observations about the combined impact of healthy lifestyle and GLP-1 RA use on cardiovascular risk.
"It is important to keep in mind that a healthy lifestyle is often associated with confounding variables that could bias the results, such as other health behaviors or socioeconomic status. Hence, interpreting the findings should be done thoughtfully," said Ndumele, who is the director of Obesity and Cardiometabolic Research at Johns Hopkins School of Medicine.
"Nonetheless, these findings suggest that a healthy lifestyle really complements the powerful effects of GLP-1RAs. Rather than medications versus lifestyle, health care professionals should really be emphasizing both to achieve the best clinical outcomes for our patients."
Study limitations include that the estimations were based on observational data; the study group primarily consisted of white male veterans, so the findings may not be applicable to a more diverse population; and the research does not predict how the rates of cardiovascular risk may change for adults without type 2 diabetes who take GLP-1 RA medications to treat obesity.
Provided by American Heart Association
This story was originally published on Medical Xpress. 2025-11-03T10:19:06Z